|
| 36651490 | Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway. | J Cell Mol Med | 2023 |
| 37356470 | Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma. | Cancer Lett | 2023 |
| 34964999 | Conditional deletion of mTOR discloses its essential role in early B-cell development. | Mol Carcinog | 2022 |
| 35320977 | The Molecular Mechanism of Hepatic Lipid Metabolism Disorder Caused by NaAsO<sub>2</sub> through Regulating the ERK/PPAR Signaling Pathway. | Oxid Med Cell Longev | 2022 |
| 34116288 | Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity. | Int Immunopharmacol | 2021 |
| 34485146 | Chronic Stress Activates PlexinA1/VEGFR2-JAK2-STAT3 in Vascular Endothelial Cells to Promote Angiogenesis. | Front Oncol | 2021 |
| 32923678 | Mouse tumor susceptibility genes identify drug combinations for multiple myeloma. | J Cancer Metastasis Treat | 2020 |
| 31898340 | Attenuation of immune-mediated bone marrow damage in conventionally housed mice. | Mol Carcinog | 2020 |
| 33066043 | A Small Molecule Stabilizer of the MYC G4-Quadruplex Induces Endoplasmic Reticulum Stress, Senescence and Pyroptosis in Multiple Myeloma. | Cancers (Basel) | 2020 |
| 32747423 | Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis. | Mol Cancer Ther | 2020 |
| 32858886 | Conventional Co-Housing Modulates Murine Gut Microbiota and Hematopoietic Gene Expression. | Int J Mol Sci | 2020 |
| 31548308 | The transcription factor MZF1 differentially regulates murine <i>Mtor</i> promoter variants linked to tumor susceptibility. | J Biol Chem | 2019 |
| 30315240 | Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. | Nat Commun | 2018 |
| 28522584 | Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation. | Mol Cancer Ther | 2017 |
| 29133782 | mTOR intersects antibody-inducing signals from TACI in marginal zone B cells. | Nat Commun | 2017 |
| 26607598 | Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy. | Clin Cancer Res | 2016 |
| 26462961 | Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression. | ACS Chem Biol | 2016 |
| 24429254 | TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. | Mol Oncol | 2014 |
| 23357051 | A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses. | J Immunol Methods | 2013 |
| 23858034 | B cell-specific deficiencies in mTOR limit humoral immune responses. | J Immunol | 2013 |
| 23994476 | Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. | Cell Rep | 2013 |
| 21079150 | Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. | Blood | 2011 |
| 22053105 | mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. | Blood | 2011 |
| 19654412 | Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility. | Blood | 2009 |
| 15778400 | Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. | J Immunol | 2005 |
| 12831458 | TLR2 and TLR4 agonists stimulate unique repertoires of host resistance genes in murine macrophages: interferon-beta-dependent signaling in TLR4-mediated responses. | J Endotoxin Res | 2003 |
| 12925671 | Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. | J Exp Med | 2003 |
| 14634209 | Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. | Proc Natl Acad Sci U S A | 2003 |
| 12700664 | p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. | Oncogene | 2003 |
| 11896392 | TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. | Nat Immunol | 2002 |
| 12537697 | The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro. | J Endotoxin Res | 2002 |
| 11113205 | Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. | Mol Cell Biol | 2001 |
| 10396076 | The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors. | Curr Top Microbiol Immunol | 1999 |
| 9482902 | Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. | Proc Natl Acad Sci U S A | 1998 |